Evidence map›Paper›PMID 39503721›Full record

ArticleMicrobial biotechnology2024

Enhanced biosynthesis of poly(3-hydroxybutyrate) in engineered strains of Pseudomonas putida via increased malonyl-CoA availability.

Giusi Favoino, Nicolas Krink, Tobias Schwanemann, Nick Wierckx, Pablo I Nikel

Abstract read
In one paragraph

Article in Microbial biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Multi-layered metabolic remodeling ofMetabolic engineering communications · 2026
    Article
  3. Article
  4. Leveraging EngineeredACS synthetic biology · 2025
    Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Giusi FavoinoThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-9984-2886
Nicolas KrinkThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-9878-5656
Tobias SchwanemannInstitute of Bio- and Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich GmbH, Jülich, Germany.ORCID 0000-0002-6045-6793
Nick WierckxInstitute of Bio- and Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich GmbH, Jülich, Germany.ORCID 0000-0002-1590-1210
Pablo I NikelThe Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Lyngby, Denmark.ORCID 0000-0002-9313-7481

Funding

Novo Nordisk Fonden NNF10CC1016517Novo Nordisk Fonden NNF18CC0033664Novo Nordisk Fonden NNF23OC0083631
6 · The paper itself

Abstract

Malonyl-coenzyme A (CoA) is a key precursor for the biosynthesis of multiple value-added compounds by microbial cell factories, including polyketides, carboxylic acids, biofuels, and polyhydroxyalkanoates. Owing to its role as a metabolic hub, malonyl-CoA availability is limited by competition in several essential metabolic pathways. To address this limitation, we modified a genome-reduced Pseudomonas putida strain to increase acetyl-CoA carboxylation while limiting malonyl-CoA utilization. Genes involved in sugar catabolism and its regulation, the tricarboxylic acid (TCA) cycle, and fatty acid biosynthesis were knocked-out in specific combinations towards increasing the malonyl-CoA pool. An enzyme-coupled biosensor, based on the rppA gene, was employed to monitor malonyl-CoA levels in vivo. RppA is a type III polyketide synthase that converts malonyl-CoA into flaviolin, a red-colored polyketide. We isolated strains displaying enhanced malonyl-CoA availability via a colorimetric screening method based on the RppA-dependent red pigmentation; direct flaviolin quantification identified four engineered strains had a significant increase in malonyl-CoA levels. We further modified these strains by adding a non-canonical pathway that uses malonyl-CoA as precursor for poly(3-hydroxybutyrate) biosynthesis. These manipulations led to increased polymer accumulation in the fully engineered strains, validating our general strategy to boost the output of malonyl-CoA-dependent pathways in P. putida.

Indexed as

HydroxybutyratesMalonyl Coenzyme AMetabolic EngineeringPolyestersPseudomonas putidaBiosensing TechniquesGene Knockout TechniquesMetabolic Networks and PathwaysPolyhydroxybutyratesHydroxybutyratesMalonyl Coenzyme Apoly-beta-hydroxybutyratePolyestersPolyhydroxybutyrates

Identifiers

PMID39503721
PMCPMC11539682

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.